Transformational Breast Cancer MTD Support Tool
Dramatically Faster Breast Cancer Recurrence Risk Quantification
What is the Digistain Test?
Digistain is an MHRA-cleared, UKCA-marked AI-enabled quantitative histopathology platform designed to assess the risk of recurrence in breast cancer patients following surgery. It provides risk stratification information to support MDT discussion; not intended to replace clinical judgement.
The test generates a clear, easy-to-interpret risk stratification output. By providing clinicians with crucial insights, Digistain supports the development of personalised treatment plans, ensuring patients receive the best possible care while avoiding unnecessary chemotherapy.
Digistain is for invasive breast cancer patients who are:
Stage I - II
HER2-
ER+
up to 3 positive lymph nodes
Why Digistain?
Traditional methods of breast cancer risk stratification are slow and expensive, using costly reagents and taking 2-8 weeks to deliver results.
Digistain operates on routine FFPE tissue sections, requiring no molecular extraction and integrating seamlessly into existing histopathology workflows — delivering actionable results at a fraction of the cost and time of conventional methods.
Key Benefits:
CLEAR insights on likelihood of breast cancer recurrence within the next 10 years
FAST actionable results helping reduce treatment decision times
LOWER COST enables many more people to access cancer recurrence prediction tests
SEAMLESS integration with existing clinical workflows
Our Technology
Risk Actionable Information in Under 1 Hour
Digistain was created by a team of world-class cancer specialists to solve the time, cost, availability, and accuracy issues associated with traditional biomarker analytics.
Our optical scan technology captures a unique spectral signature from each biopsy creating over 10,000 data points unique to the individual biology of a patient. We then use artificial intelligence to analyse the imaging data and calculate a Digistain Prognostic Score that precisely and objectively identifies the risk of cancer recurrence.
Supported by
Awards
